Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma.
Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, Melaiu O, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: gemignani f. Int J Mol Sci. 2020 Jul 9;21(14):4856. doi: 10.3390/ijms21144856. Int J Mol Sci. 2020. PMID: 32659970 Free PMC article.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: gemignani f. Invest New Drugs. 2021 Jun;39(3):644-657. doi: 10.1007/s10637-020-01040-y. Epub 2020 Dec 9. Invest New Drugs. 2021. PMID: 33300108 Free PMC article.
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.
Dell'Anno I, Melani A, Martin SA, Barbarino M, Silvestri R, Cipollini M, Giordano A, Mutti L, Nicolini A, Luzzi L, Aiello R, Gemignani F, Landi S. Dell'Anno I, et al. Among authors: gemignani f. Cancers (Basel). 2022 May 20;14(10):2527. doi: 10.3390/cancers14102527. Cancers (Basel). 2022. PMID: 35626133 Free PMC article.
Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S. Melaiu O, et al. Among authors: gemignani f. Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. Mutat Res. 2015. PMID: 25771974 Clinical Trial.
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S. Melaiu O, et al. Among authors: gemignani f. Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129. Genes Cancer. 2017. PMID: 28435517 Free PMC article.
267 results